Evaluation of strategies to increase efficacy and prevent relapse with IDH inhibitors are ongoing, including clinical investigations of treatment combinations with standard anti-leukemia therapies (i.e., intensive chemotherapy, hypomethylating agents) as well as rational combinations (venetoclax) and agents targeted against AML resistance pathways (i.e., FLT3, RAS, other RTK pathway inhibitors). The gene discussed is IDH2; the disease is acute myeloid leukemia.